Humira OKed in EU to treat forms of non-infectious uveitis

US pharma major AbbVie’s (NYSE: ABBV) mega-blockbuster drug Humira (adalimumab) has today received approval from the European Medicines Agency as the first and only biologic medicine authorized for patients with certain types of non-infectious uveitis, an inflammatory, painful eye condition  that can lead to blindness.

Adalimumab is now authorized in the European Union as a treatment option for uveitis affecting the middle, back or multiple parts of the eye, called the uvea, and can be used in adults for whom typical treatment with corticosteroids is insufficient in controlling the inflammation, or where that treatment has started to cause complications.

Just last week, Humira, the world’s biggest-selling drug with 2015 revenues of $14 billion, gained US Food and Drug Administration approval for the treatment of non-infectious intermediate, posterior and panuveitis, making it the tenth indication for the drug in the USA.